Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 27742873.
- Also identified by DOI 10.1136/thoraxjnl-2016-209063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Latent TB infection (LTBI) screening and treatment in HIV-positive individuals in the UK is advocated by the British HIV Association (BHIVA) and National Institute for Health and Care Excellence (NICE), although each recommends differing strategies. We undertook an evaluation of UK practice, relating the responses to the local HIV/TB disease burden. 162 of 188 (86%) UK geographical areas responded; only 93/162 (57.4%) offer LTBI testing with considerable heterogeneity in practice, and no difference in HIV/TB burden between areas offering testing and those who do not. Only 33/93 (35.5%) and 6/93 (6.5%) reported full compliance with BHIVA and NICE guidance respectively. A uniform national guideline is required.
Medical subject headings
- AIDS-Related Opportunistic Infections
- Latent Tuberculosis
- Mass Screening